clinical trial · NCT07590531
AMT-116 in Combination With AK112 in Patients With Lung Cancer
Advanced Non-small Cell Lung Cancer (NSCLC)AMT-116AK112
brief summary
The purpose of this study is to evaluate the safety and efficacy of AMT-116 in combination with Ivonescimab (AK112) in patients with advanced non-small cell lung cancer (NSCLC). The study is divided into two parts: the part I is dose escalation and the Part Ⅱ for expansion.
started
Jun 29, 2026
primary completion
May 30, 2027
completion
Dec 31, 2027
last updated
Aug 10, 2026
official title
An Open-label, Multicenter Phase Ib/II Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMT116 in Combination With Ivonescimab (AK112) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol